Q-omics provides the consensus-scored TRPC5OS profile across patient tissues and cancer cell-line models. TRPC5OS expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, TRPC5OS is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, TRPC5OS RNA expression shows 13,081 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and KICH as cancer lineages where TRPC5OS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPC5OS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPC5OS survival associations across molecular data types. TRPC5OS RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPC5OS RNA expression–survival associations across cancer types. High TRPC5OS expression shows unfavorable associations in UVM, KIRP, LGG and BLCA, but favorable associations in SKCM and BRCA. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for TRPC5OS RNA expression.
This table summarizes TRPC5OS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TRPC5OS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPC5OS shows lower tumor expression in KICH, KIRC and KIRP and higher tumor expression in THCA, CHOL and LIHC. The KICH box plot shows higher TRPC5OS RNA expression in normal versus tumor tissue (log2 FC = −0.533, t-test p < 0.001).
This table shows molecular features associated with TRPC5OS in patient tissues and cancer cell lines. In patient samples, TRPC5OS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPC5OS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
